Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine

Figure 1 Mean serum b2m levels for each follow-up interval, plotted separately for the subgroup A1 of lamivudine monotherapy treated patients who exhibited VB (square markers) and for the subgroup A2 of patients who did not (triangle markers), as well for the group B of patients who received initial combination (interferon plus lamivudine) treatment (rhombus markers), followed by lamivudine monotherapy thereafter.